Medifast Inc. Files Q3 2024 10-Q Report
Ticker: MED · Form: 10-Q · Filed: Nov 4, 2024 · CIK: 910329
Sentiment: neutral
Topics: 10-Q, earnings, financials
TL;DR
Medifast Q3 2024 10-Q filed. Key financials out.
AI Summary
Medifast Inc. reported its third-quarter results for the period ending September 30, 2024. The company's financial performance for this quarter and the year-to-date period is detailed in this 10-Q filing. Specific revenue, profit, and balance sheet figures for Q3 2024 and the first nine months of 2024 are presented.
Why It Matters
This filing provides investors with the official financial performance of Medifast Inc. for the third quarter of 2024, crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: medium — 10-Q filings are standard financial reports, but the specific numbers within can indicate significant financial health changes.
Key Numbers
- 2024 Q3 — Reporting Period (Third quarter of 2024)
- 2024-09-30 — End of Reporting Period (Specific date for Q3 financial data)
- 2024-01-01 — Start of Year-to-Date Period (Beginning of the nine-month period)
- 2023-12-31 — Prior Year End (Balance sheet data reference)
Key Players & Entities
- MEDIFAST INC (company) — Filer
- 20240930 (date) — Conformed Period of Report
- 20241104 (date) — Filed as of Date
- 001-31573 (company) — SEC File Number
FAQ
What is the reporting period for this 10-Q filing?
The conformed period of report is 20240930, indicating the third quarter of 2024.
When was this 10-Q filing submitted?
This filing was submitted on 20241104.
What is the company's SEC file number?
The SEC file number for Medifast Inc. is 001-31573.
What is Medifast Inc.'s fiscal year end?
Medifast Inc.'s fiscal year ends on 1231.
What is the company's primary business address?
The company's business address is 11445 CRONHILL DRIVE, OWINGS MILLS, MD 21117.
Filing Stats: 4,742 words · 19 min read · ~16 pages · Grade level 14.9 · Accepted 2024-11-04 16:50:52
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share MED New York Stock Exchange
Filing Documents
- med-20240930.htm (10-Q) — 990KB
- med-20240930xexx311.htm (EX-31.1) — 10KB
- med-20240930xexx312.htm (EX-31.2) — 10KB
- med-20240930xexx321.htm (EX-32.1) — 7KB
- 0001628280-24-045040.txt ( ) — 5163KB
- med-20240930.xsd (EX-101.SCH) — 32KB
- med-20240930_cal.xml (EX-101.CAL) — 65KB
- med-20240930_def.xml (EX-101.DEF) — 127KB
- med-20240930_lab.xml (EX-101.LAB) — 496KB
- med-20240930_pre.xml (EX-101.PRE) — 325KB
- med-20240930_htm.xml (XML) — 654KB
– Financial Statements
Item 1 – Financial Statements Condensed Consolidated Statements of Operations (unaudited) for the Three and Nine Months Ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three and Nine Months Ended September 30, 2024 and 2023 3 Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2024 and December 31, 2023 4 Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Three and Nine Months Ended September 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements (unaudited) 8
– Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 17
– Quantitative and Qualitative Disclosures about Market Risk
Item 3 – Quantitative and Qualitative Disclosures about Market Risk 28
– Controls and Procedures
Item 4 – Controls and Procedures 29
– Other Information
Part II – Other Information
– Legal Proceedings
Item 1 – Legal Proceedings 30
– Risk Factors
Item 1A – Risk Factors 30
– Unregistered Sales of Equity Securities and Use of Proceeds
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds 30
– Exhibits
Item 6 – Exhibits 31 1 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (U.S. dollars in thousands, except per share amounts & dividend data) Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 Revenue $ 140,163 $ 235,869 $ 483,460 $ 881,039 Cost of sales 34,489 58,492 127,056 246,558 Gross profit 105,674 177,377 356,404 634,481 Selling, general, and administrative 103,568 151,868 354,235 516,755 Income from operations 2,106 25,509 2,169 117,726 Other (expense) income Interest income 1,333 1,033 3,851 1,314 Other (expense) income ( 1,861 ) 7 ( 3,508 ) ( 45 ) ( 528 ) 1,040 343 1,269 Income before provision for income taxes 1,578 26,549 2,512 118,995 Provision for income taxes 449 3,418 1,222 25,615 Net income $ 1,129 $ 23,131 $ 1,290 $ 93,380 Earnings per share - basic $ 0.10 $ 2.12 $ 0.12 $ 8.58 Earnings per share - diluted $ 0.10 $ 2.12 $ 0.12 $ 8.55 Weighted average shares outstanding Basic 10,937 10,892 10,928 10,881 Diluted 10,971 10,933 10,959 10,925 Cash dividends declared per share $ — $ 1.65 $ — $ 4.95 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (U.S. dollars in thousands) Three months ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Net income $ 1,129 $ 23,131 $ 1,290 $ 93,380 Other comprehensive income, net of tax: Foreign currency translation 4 27 47 125 Unrealized net gains (losses) on investment securities 319 ( 9 ) 54 ( 9 ) 323 18 101 116 Comprehensive income $ 1,452 $ 23,149 $ 1,391 $ 93,496 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)